Bristol-Myers Squibb Co. (NYSE:BMY) shares, rose in value, with the stock price down by -0.27% to the previous day’s close as strong demand from buyers drove the stock to $48.86.
Actively observing the price movement in the last trading, the stock closed the session at $48.99. The PE ratio was 12.67 over 12-month period. Referring to stock’s 52-week performance, its high was $70.93, and the low was $47.58. On the whole, BMY has fluctuated by -6.49% over the past month.
The company’s Forward Dividend Ratio is 2.34, with its dividend yield at 4.79%.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that BMY’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of BMY currently trading nearly -3.35% and -4.40% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 39.23, while the 7-day volatility ratio is showing 1.42% which for the 30-day chart, stands at 1.61%. Furthermore, Bristol-Myers Squibb Co. (BMY)’s beta value is 0.41, and its average true range (ATR) is 0.85.
A comparison of Bristol-Myers Squibb Co. (BMY) with its peers suggests the former has fared considerably weaker in the market. BMY showed an intraday change of -0.27% in last session, and over the past year, it shrunk by -30.73%%.
Data on historical trading for Bristol-Myers Squibb Co. (NYSE:BMY) indicates that the trading volumes over the past 3 months, they’ve averaged 15.43 million. According to company’s latest data on outstanding shares, there are 2.03 billion shares outstanding.
Nearly 0.08% of Bristol-Myers Squibb Co.’s shares belong to company insiders and institutional investors own 78.20% of the company’s shares. The stock has fallen by -4.77% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the BMY stock heading into the next quarter.
